Roth Lawrence M, Lyu Bingjian, Cheng Liang
Department of Pathology and Laboratory Medicine, Indiana University School of Medicine, Indianapolis, IN 46202.
Department of Pathology, Women's Hospital, School of Medicine, Zhejiang University, 310003, China.
Hum Pathol. 2017 Jul;65:1-14. doi: 10.1016/j.humpath.2017.04.009. Epub 2017 Apr 23.
Sex cord-stromal tumors (SCSTs) are the second most frequent category of testicular neoplasms, accounting for approximately 2% to 5% of cases. Both genetic and epigenetic factors account for the differences in frequency and histologic composition between testicular and ovarian SCSTs. For example, large cell calcifying Sertoli cell tumor and intratubular large cell hyalinizing Sertoli cell neoplasia occur in the testis but have not been described in the ovary. In this article, we discuss recently described diagnostic entities as well as inconsistencies in nomenclature used in the recent World Health Organization classifications of SCSTs in the testis and ovary. We also thoroughly review the topic of neoplasms composed of both germ cells and sex cord derivatives with an emphasis on controversial aspects. These include "dissecting gonadoblastoma" and testicular mixed germ cell-sex cord stromal tumor (MGC-SCST). The former is a recently described variant of gonadoblastoma that sometimes is an immediate precursor of germinoma in the dysgenetic gonads of patients with a disorder of sex development. Although the relationship of dissecting gonadoblastoma to the previously described undifferentiated gonadal tissue is complex and not entirely resolved, we believe that it is preferable to continue to use the term undifferentiated gonadal tissue for those cases that are not neoplastic and are considered to be the precursor of classical gonadoblastoma. Although the existence of testicular MGC-SCST has been challenged, the most recent evidence supports its existence; however, testicular MGC-SCST differs significantly from ovarian examples due to both genetic and epigenetic factors.
性索间质肿瘤(SCSTs)是睾丸肿瘤中第二常见的类型,约占病例的2%至5%。遗传和表观遗传因素均导致了睾丸和卵巢SCSTs在发病率和组织学构成上的差异。例如,大细胞钙化性支持细胞瘤和小管内大细胞透明变性支持细胞瘤仅发生于睾丸,卵巢中尚未见报道。在本文中,我们讨论了最近描述的诊断实体以及世界卫生组织(WHO)对睾丸和卵巢SCSTs分类中命名的不一致之处。我们还全面回顾了由生殖细胞和性索衍生物组成的肿瘤这一主题,重点关注有争议的方面。这些包括“分割型性腺母细胞瘤”和睾丸混合性生殖细胞-性索间质肿瘤(MGC-SCST)。前者是性腺母细胞瘤的一种新描述的变异型,有时是性发育障碍患者发育异常性腺中生殖细胞瘤的直接前体。尽管分割型性腺母细胞瘤与先前描述的未分化性腺组织的关系复杂且尚未完全解决,但我们认为对于那些非肿瘤性且被认为是经典性腺母细胞瘤前体的病例,继续使用未分化性腺组织这一术语更为合适。尽管睾丸MGC-SCST的存在受到了质疑,但最新证据支持其存在;然而,由于遗传和表观遗传因素,睾丸MGC-SCST与卵巢的病例有显著差异。